First identified in patients with B cell chronic lymphocytic leukaemia, Bcl-3 was shown to function as a coactivator or inhibitor with dimers of the NF-κB subunits p50 and p52 to regulate the transcription of NF-κB target genes. This evidence concerns the gene NFKB1 and B-cell chronic lymphocytic leukemia.